Andrew Lee is the Founder and Managing Director for StartX Med, the 501(c)3 Medical Accelerator of Stanford University and Stanford Hospital. At StartX, Andrew leads investments in biotechnology, FDA/CLIA regulated products, and healthcare/life science enterprise. To date, he has supported over 200 medical portfolio companies and 25+ FDA approved products in the biotech, med device, and digital health/ AI spaces with $2B+ in cumulative funding since 2012. He is also the Founder and Managing Director of StartX-QB3 Labs, a joint medical science and engineering venture between Stanford’s StartX and UCSF’s QB3 programs. Andrew is the Founder/CEO of Spot Biosystems, a venture-backed gene therapy company supported by Stanford Hospital. Andrew received his MD/Ph.D. from Stanford University School of Medicine.